AI Terminal
STRATEC SE
M&A Activity • Jul 1, 2016
416_rns_2016-07-01_e85763c1-80b4-4138-97a6-856db7db00c8.html
M&A Activity
Open in ViewerOpens in native device viewer
News Details
Corporate | 1 July 2016 11:38
STRATEC completes acquisition of Sony DADC BioSciences
DGAP-News: STRATEC Biomedical AG / Key word(s): Takeover/Acquisition
2016-07-01 / 11:38
The issuer is solely responsible for the content of this announcement.
STRATEC completes acquisition of Sony DADC BioSciences
Birkenfeld, July 1, 2016
STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) today announces the successful completion of the acquisition of Sony DADC BioSciences GmbH (‘BioSciences’), a leading global OEM supplier of smart consumables for diagnostics, life sciences and medical technology applications.
On June 8, 2016, STRATEC announced that it signed an agreement with Sony DADC Austria AG (‘Sony DADC’), based in Anif/Salzburg, Austria, to acquire all of the shares of BioSciences, a wholly-owned subsidiary of Sony DADC.
The joining of these companies will enlarge STRATEC’s capabilities to serve its customers, by combining macro-and microfluidic solutions as well as offering services spanning sample preparation solutions, software, instrument automation and polymer consumables development and manufacturing. The acquisition diversifies STRATEC’s overall customer structure and extends the value chain significantly.
Going forward, the business will operate under the name of STRATEC Consumables.
The consolidation will start with July, 1, 2016.
About STRATEC
STRATEC Biomedical AG ( www.stratec.com ) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers sample preparation solutions, integrated laboratory software, and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain – from development to design and production through to quality assurance.
The partners market the systems, software and consumables in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
Sandra Eberle, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916-197
Fax: +49 7082 7916-999
STRATEC Consumables
Ricarda Pichler, Marketing
Sonystr. 20, A-5081 Anif/Salzburg
Austria
Phone: +43 6246 880 8142
Fax: +43 6246 880 9187
2016-07-01 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | STRATEC Biomedical AG |
| Gewerbestr. 37 | |
| 75217 Birkenfeld | |
| Germany | |
| Phone: | +49 (0)7082 7916 0 |
| Fax: | +49 (0)7082 7916 999 |
| E-mail: | [email protected] |
| Internet: | www.stratec.com |
| ISIN: | DE000STRA555 |
| WKN: | STRA55 |
| Indices: | TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX |
| End of News | DGAP News Service |